Peter M. Anderson, MD, PhD , Cleveland Clinic, Cleveland, OH, talks on the development of personalized medicine approaches for patients with neuroendocrine tumors (NETs), and the importance of targeting unique, targetable somatic mutations as well as the potential of RNA cancer vaccines for patients with NETs. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.